Last reviewed · How we verify
NCT02285244
Sotrastaurin Acetate in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, Prolymphocytic Leukemia, or Richter's Transformation
Phase 2 trial testing sotrastaurin acetate in Prolymphocytic Leukemia. Withdrawn.
12 March 2015
Quick facts
| Lead sponsor | James Blachly |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 12 March 2015 |
| Primary completion | 12 March 2015 |
| Estimated completion | 12 March 2015 |
Drugs / interventions tested
- sotrastaurin acetate — full drug profile →
- pharmacological study — full drug profile →
- laboratory biomarker analysis — full drug profile →
Conditions studied
- Prolymphocytic Leukemia — all drugs for Prolymphocytic Leukemia →
- Recurrent Mantle Cell Lymphoma — all drugs for Recurrent Mantle Cell Lymphoma →
- Recurrent Small Lymphocytic Lymphoma — all drugs for Recurrent Small Lymphocytic Lymphoma →
- Refractory Chronic Lymphocytic Leukemia — all drugs for Refractory Chronic Lymphocytic Leukemia →
Sponsor
James Blachly
Who can join
18 and older, any sex, with Prolymphocytic Leukemia or Recurrent Mantle Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase II trial studies how well sotrastaurin acetate works in treating patients with chronic lymphocytic leukemia, small lymphocytic leukemia, prolymphocytic leukemia, or Richter's transformation that has returned or that does not respond to treatment. Sotrastaurin acetate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
WNT Signaling in Hematological Malignancies.
Frenquelli M, Tonon G. · · 2020 · cited 34× · PMID 33409156 · DOI 10.3389/fonc.2020.615190
Verify or expand the search:
- PubMed search for NCT02285244
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Prolymphocytic Leukemia
Currently open trials in the same condition.
- NCT05805605 — Allo HSCT Using RIC and PTCy for Hematological Diseases · Phase 2 · recruiting
- NCT04195633 — Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological M · Phase 2 · recruiting
- NCT04411043 — Observatory of Prolymphocytic Leukemia T · recruiting
- NCT03314974 — Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · Phase 2 · recruiting
- NCT02029443 — ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, · Phase 1, PHASE2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02285244 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by James Blachly
- Last refreshed: 5 April 2017
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02285244.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing